EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 < 50%N. Rizvi,S. Lee,P. Curtis,W. Caldwell,B. Gao,P. RietschelJOURNAL OF THORACIC ONCOLOGY（2018）引用 0|浏览6暂无评分关键词Anti-PD-1,cemiplimab,REGN2810AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
